Novocure Advances Tumor Treating Fields Technology For Patients With Newly Diagnosed Glioblastoma
Executive Summary
Novocure’s tumor treating fields technology offers hope to the 10,000 to 12,000 patients in the US diagnosed with glioblastoma multiforme (GBM), the most common and deadliest form of malignant primary brain tumor. The EF-14 Phase III clinical trial evaluating the company’s Optune device for newly diagnosed GBM was terminated due to early success, and in December 2014, the FDA approved an IDE supplement allowing all control patients in the trial to receive the treatment.
You may also be interested in...
NovoCure’s Tumor Treating Fields Help Mesothelioma Patients Live Longer In STELLAR Trial
New results from the Phase II STELLAR trial shows Tumor Treating Fields therapy in conjunction with chemotherapy extends survival in previously untreated mesothelioma patients with no safety problems.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.